Market Overview

The expansion of hemophilic patient pool and rise in adoption of intravenous immunoglobulin treatment are observed to bolster the market growth. The availability of modern technologies for the production of immunoglobulin solutions and their purification can impact the IVIg market expansion. However, strict government norms regarding intravenous immunoglobulin products manufacturing and launch, and increase in awareness about side effects of immunoglobin treatment can hinder the market rise. On the contrary, the high rate of adoption of IVIg for treating diseases, such as; CIDP and hypogammaglobulinemia among others can counter the market slow-down due to surfacing challenges.

Market Research Future (MRFR) studied the global intravenous immunoglobulin (IVIg) market 2020 along the analysis tenure till 2027. By 2027, the intravenous immunoglobulin (IVIg) market is likely to rise at 6.30% CAGR. On the conclusion of the study period, the intravenous immunoglobulin (IVIg) market is expected to touch USD 10,485.86 Mn.

Market Segmentation

The segment study of the global intravenous immunoglobulin (IVIg) market is based on application and on type.

The type-based segments of the global intravenous immunoglobulin market are IgA, IgG, IgD, and IgE. The sub segments of the IgA market are IgA2 and IgA1. The high success rate of IgA treatment can promote expansion of the market. The expansion of the IgA segment can be attribute to the surge in number of clinical trials and intravenous product approvals for latest clinical applications. A gradual increase in healthcare expenditure and increase in awareness about autoimmune diseases that facilitate the demand for IVIG therapies to treat primary and acquired immunodeficiency diseases can bolster the IgA segment growth. Sedentary lifestyle initiating disorders, such as; antibody deficiency and obesity are creating the need for immunology treatment that can drive the market growth.

The application-based segments of the global intravenous immunoglobulin market are CIDP, Hypogammaglobulinemia, Miller Fisher syndrome, Guillain-Barre syndrome, Multifocal Motor Neuropathy, Myasthenia Gravis, Immunodeficiency diseases, acute motor-sensory axonal neuropathy, severe combined immunodeficiency, common variable immunodeficiency, Primary Humoral Immunodeficiency, Guillain-Barre syndrome, Kawasaki disease, ITP, acute motor-sensory axonal neuropathy. The sub-segments of the CIDP segment are progressive, monophasic, and recurrent.

Regional Analysis                  

In North America, the intervenors immunoglobulin market is expected to acquire financial gain due to the increase in awareness about different products used in the treatment of different immunodeficiency diseases. The growing inclination of physicians towards different therapies and rise in healthcare expenses can be attributed to the growth of North America market.

Changes in lifestyle and expansion of ageing population are expected to contribute to the rise of intravenous immunoglobin industry in the years to come. In addition, the surge in incidences of PID, chronic disorder, and autoimmune diseases can add to the regional market upsurge.

In Asia Pacific, the intravenous immunoglobin market is expected to exhibit high CAGR and hold lucrative growth scopes over the review period. The rise in awareness about potential opportunities for the immunoglobulin-based therapies in the region and easy accessibility of treatment for primary immune deficiencies can benefit the regional market in the near future.

Increase in healthcare spending and growing preference for IV immunoglobulin treatment can favor the market in MEA. The adoption of different medical business models, increase in cases of immune disorders, and surge in awareness about intravenous and subcutaneous immunoglobulin therapies can contribute to the rise of the regional market.

Key Players

ABEONA THERAPEUTICS (US), Biotest AG.(Germany), Baxter (US), China Biologic Products, Inc. (China), BDI Pharma (US), CSL Behring (US), Kedrion S.p.A (us), Grifols Inc. (Spain), Octapharma (Switzerland), and Shire (Republic of Ireland) are some reputed players in the global intravenous immunoglobulin (IVIg) market that are profiled by MRFR. Key players are focusing on their global reputation by boosting their market penetration strategies, and other related details are discussed in the report.